Monte Rosa Therapeutics, Inc. Common Stock (GLUE) is a publicly traded Healthcare sector company. As of May 21, 2026, GLUE trades at $18.62 with a market cap of $1.52B and a P/E ratio of 0.00. GLUE moved +6.09% today. Year to date, GLUE is +29.51%; over the trailing twelve months it is +348.32%. Its 52-week range spans $3.50 to $25.77. Analyst consensus is strong buy with an average price target of $32.80. Rallies surfaces GLUE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Monte Rosa Therapeutics Posts $0.45 Q1 Loss, Misses Revenue Estimates: Monte Rosa Therapeutics posted a Q1 net loss of $0.45 per share, wider than the $0.28-per-share loss analysts forecast, versus a $0.57-per-share profit in Q1 2025. Its first-quarter revenue also fell short of consensus estimates.
| Metric | Value |
|---|---|
| Price | $18.62 |
| Market Cap | $1.52B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $25.77 |
| 52-Week Low | $3.50 |
| Volume | 6 |
| Avg Volume | 0 |
| Revenue (TTM) | $75.62M |
| Net Income | $-72.70M |
| Gross Margin | 0.00% |
7 analysts cover GLUE: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $32.80.